 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "MDMAI" – news ·newspapers ·books ·scholar ·JSTOR(October 2014) |
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 5,6-Methylenedioxy-N-methyl-2-aminoindane; MDMAI |
| Routes of administration | Oral |
| Drug class | Serotonin releasing agent;Entactogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H13NO2 |
| Molar mass | 191.230 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
5,6-Methylenedioxy-N-methyl-2-aminoindane (MDMAI), is adrug of the2-aminoindane group developed in the 1990s by a team led byDavid E. Nichols atPurdue University. It acts as a non-neurotoxicserotonin releasing agent in animals and is a putativeentactogen in humans.[1]
MDMAI can be thought of as a cyclisedanalogue ofMDMA where the alpha-methyl carbon of the alkylamino side chain has been joined back round to the 6-position of the aromatic ring to form anindane ring system. This changes the core structure of the molecule fromphenethylamine toaminoindane, and causes the pharmacological properties of the two compounds to be substantially different.[1]
